Parkman Healthcare Partners’s Precigen PGEN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-1,002,826
Closed -$4.19M 105
2025
Q4
$4.19M Sell
1,002,826
-1,098,889
-52% -$4.25M 0.4% 68
2025
Q3
$6.91M Buy
2,101,715
+558,892
+36% +$1.58M 0.72% 52
2025
Q2
$2.19M Sell
1,542,823
-1,648,520
-52% -$2.34M 0.25% 80
2025
Q1
$4.76M Buy
+3,191,343
New +$5.02M 0.56% 51

Other funds holding PGEN

Parkman Healthcare Partners's PGEN Position: Q1 2026 in Review

Parkman Healthcare Partners sold out of Precigen (PGEN) in Q1 2026, closing a stake of 1,002,826 shares — an estimated $4.19M sold.

Parkman Healthcare Partners first reported a position in PGEN in Q1 2025 and held it in 4 quarters. The position peaked at $6.91M in Q3 2025. 206 funds tracked by Wall St. Rank hold PGEN as of Q1 2026.

  • Parkman Healthcare Partners reported no remaining Precigen position as of Q1 2026 after selling out during the quarter.
  • Parkman Healthcare Partners sold 1,002,826 Precigen shares in Q1 2026, an estimated $4.19M.
  • Parkman Healthcare Partners first reported a position in Precigen in Q1 2025 and held it in 4 quarters.
  • Parkman Healthcare Partners's Precigen position peaked at $6.91M in Q3 2025.
  • 206 funds tracked by Wall St. Rank held Precigen as of Q1 2026.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.